Expression profiling reveals hepsin overexpression in prostate cancer.
Prostate cancer is the most commonly diagnosed noncutaneous cancer in men. Despite this fact, many of the genetic changes that coincide with prostate cancer progression remain enigmatic. We have addressed this problem by characterizing the expression profiles of several benign and malignant human prostate samples, and we have identified several genes that are differentially expressed between benign and malignant glands. One gene that was overexpressed encodes the serine protease hepsin. We used an independent sample set to confirm that hepsin is overexpressed in prostate tumors, and in situ hybridization demonstrates that hepsin is specifically overexpressed in the carcinoma cells themselves. These facts, together with the molecular properties of hepsin, make it an ideal target for prostate cancer therapy.
Magee
J A
JA
Department of Pathology, Division of Laboratory Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, Missouri 63110, USA.
Araki
T
T
Patil
S
S
Ehrig
T
T
True
L
L
Humphrey
P A
PA
Catalona
W J
WJ
Watson
M A
MA
Milbrandt
J
J
D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D017403:In Situ Hybridization; D008297:Male; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D012697:Serine Endopeptidases / Q000096:biosynthesis / Q000235:genetics*; D015854:Up-Regulation
D012697:Serine Endopeptidases; C055645:hepsin